Tags

Type your tag names separated by a space and hit enter

Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats.
Eur J Pharmacol. 2014 Oct 05; 740:248-54.EJ

Abstract

Liver plays a vital role in blood glucose homeostasis. Recent studies have provided considerable evidence that hepatic glucose production (HGP) plays an important role in the development of fasting hyperglycemia in diabetes. From this perspective, diminution of HGP has certainly been considered for the treatment of diabetes. In the present study, we have analyzed the modulatory effects of fisetin, a flavonoid of strawberries, on the expression of key enzymes of carbohydrate metabolism in STZ induced experimental diabetic rats. The physiological criterions such as food and fluid intake were regularly monitored. The levels of blood glucose, plasma insulin, hemoglobin and glycosylated hemoglobin were analyzed. The mRNA and protein expression levels of gluconeogenic genes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) were determined by immunoblot as well as PCR analysis. Diabetic group of rats showed significant increase in food and water intake when compared with control group of rats. Upon oral administration of fisetin as well as gliclazide to diabetic group of rats, the levels were found to be decreased. Oral administration of fisetin (10 mg/kg body weight) to diabetic rats for 30 days established a significant decline in blood glucose and glycosylated hemoglobin levels and a significant increase in plasma insulin level. The mRNA and protein expression levels of gluconeogenic genes, such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), were decreased in liver tissues upon treatment with fisetin. The results of the present study suggest that fisetin improves glucose homeostasis by direct inhibition of gluconeogenesis in liver.

Authors+Show Affiliations

Department of Biochemistry, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India.Department of Inorganic Chemistry, University of Madras, Guindy Campus, Chennai 600025, India.Department of Biochemistry, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India. Electronic address: subbus2020@yahoo.co.in.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25064342

Citation

Prasath, Gopalan Sriram, et al. "Fisetin Improves Glucose Homeostasis Through the Inhibition of Gluconeogenic Enzymes in Hepatic Tissues of Streptozotocin Induced Diabetic Rats." European Journal of Pharmacology, vol. 740, 2014, pp. 248-54.
Prasath GS, Pillai SI, Subramanian SP. Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats. Eur J Pharmacol. 2014;740:248-54.
Prasath, G. S., Pillai, S. I., & Subramanian, S. P. (2014). Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats. European Journal of Pharmacology, 740, 248-54. https://doi.org/10.1016/j.ejphar.2014.06.065
Prasath GS, Pillai SI, Subramanian SP. Fisetin Improves Glucose Homeostasis Through the Inhibition of Gluconeogenic Enzymes in Hepatic Tissues of Streptozotocin Induced Diabetic Rats. Eur J Pharmacol. 2014 Oct 5;740:248-54. PubMed PMID: 25064342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats. AU - Prasath,Gopalan Sriram, AU - Pillai,Subramanian Iyyam, AU - Subramanian,Sorimuthu Pillai, Y1 - 2014/07/24/ PY - 2014/05/22/received PY - 2014/06/13/revised PY - 2014/06/17/accepted PY - 2014/7/28/entrez PY - 2014/7/30/pubmed PY - 2015/11/4/medline KW - Fisetin KW - Glucose 6 phosphatase KW - Immunoblotting KW - PEPCK KW - RT-PCR KW - STZ diabetes SP - 248 EP - 54 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 740 N2 - Liver plays a vital role in blood glucose homeostasis. Recent studies have provided considerable evidence that hepatic glucose production (HGP) plays an important role in the development of fasting hyperglycemia in diabetes. From this perspective, diminution of HGP has certainly been considered for the treatment of diabetes. In the present study, we have analyzed the modulatory effects of fisetin, a flavonoid of strawberries, on the expression of key enzymes of carbohydrate metabolism in STZ induced experimental diabetic rats. The physiological criterions such as food and fluid intake were regularly monitored. The levels of blood glucose, plasma insulin, hemoglobin and glycosylated hemoglobin were analyzed. The mRNA and protein expression levels of gluconeogenic genes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) were determined by immunoblot as well as PCR analysis. Diabetic group of rats showed significant increase in food and water intake when compared with control group of rats. Upon oral administration of fisetin as well as gliclazide to diabetic group of rats, the levels were found to be decreased. Oral administration of fisetin (10 mg/kg body weight) to diabetic rats for 30 days established a significant decline in blood glucose and glycosylated hemoglobin levels and a significant increase in plasma insulin level. The mRNA and protein expression levels of gluconeogenic genes, such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), were decreased in liver tissues upon treatment with fisetin. The results of the present study suggest that fisetin improves glucose homeostasis by direct inhibition of gluconeogenesis in liver. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/25064342/Fisetin_improves_glucose_homeostasis_through_the_inhibition_of_gluconeogenic_enzymes_in_hepatic_tissues_of_streptozotocin_induced_diabetic_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(14)00535-4 DB - PRIME DP - Unbound Medicine ER -